HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Andrology, Vol 20, Issue 5 611–618, Copyright $^{\odot}$ 1999 by The American Society of Andrology

citeTrack

JOURNAL ARTICLE

Journal of

Serum dihydrotestosterone and testosterone concentrations in human immunodeficiency virus-infected men with and without weight loss

S. Arver, I. Sinha-Hikim, G. Beall, M. Guerrero, R. Shen and S. Bhasin

Division of Endocrinology, Metabolism, and Molecular Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California 90059, USA.

Weight loss is an important determinant of disease outcome in human immunodeficiency virus (HIV)-infected men. Others have suggested that a defect in dihydrotestosterone (DHT) generation contributes to weight loss in HIV-infected men. To determine whether DHT levels correlate

with weight loss independently of changes in testosterone levels, we prospectively measured serum total - and free-testosterone and DHT levels in 148 consecutive HIV-infected men and 42 healthy men. Thirty-one percent of HIV-infected men had serum testosterone levels less than 275 ng/dL, the lower limit of the normal male range; of these, 81% had normal or low LH and FSH levels (hypogonadotropic), and 19% had elevated LH and FSH levels (hypergonadotropic). Overall, serum testosterone, free-testosterone, and DHT levels were lower in HIV-infected men than in healthy men, but serum DHT-to-testosterone ratios were not significantly different between the two groups. Serum total - and free-testosterone levels were lower in HIV-infected men who had lost 5 lb or more of weight in the preceding 12 months than in those who had not lost any weight. Serum DHT levels and DHT-to-testosterone ratios did not differ between those who had lost weight and those who had not. Serum testosterone and free-testosterone levels, but not DHT levels, correlated with weight change and with Karnofsky performance status. We also performed a retrospective analysis of data from a previous study in which HIV-infected men with serum testosterone levels less than 400 ng/dL had been treated with placebo or testosterone patches designed to nominally release 5 mg testosterone over 24 hours. Serum testosterone-to-DHT ratios did not change after testosterone treatment. Changes in fatfree mass were correlated with changes in both serum testosterone (r = 0.42, P = 0.018) and DHT (r =0.35, P = 0.049) levels. Serum total - testosterone and DHT levels were highly correlated with one another, and when the change in serum testosterone was taken into account, serum DHT levels no longer showed a significant correlation with change in fat-free mass. We conclude that DHT levels are lower in HIV-infected men than in healthy men but that neither DHT levels nor DHT-totestosterone ratios correlate with weight loss. During testosterone treatment, serum DHT levels increase proportionately, but the increments in serum testosterone correlate with the change in fatfree mass. Our data do not support the hypothesis that a defect in DHT generation contributes to weight loss in HIV-infected men independently of changes in testosterone levels; it is possible that

This Article

- Full Text (PDF)
- Alert me when this article is cited
- Alert me if a correction is posted

Services

- Similar articles in this journal
- Similar articles in PubMed
- Alert me to new issues of the journal
- Download to citation manager

Citing Articles

- Citing Articles via HighWire
- Citing Articles via Google Scholar

Google Scholar

- Articles by Arver, S.
- Articles by Bhasin, S.
- Search for Related Content

PubMed

- PubMed Citation
- Articles by Arver, S.
- Articles by Bhasin, S.

This article has been cited by other articles:



THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM HOME

S. Bhasin, R. A. Parker, F. Sattler, R. Haubrich, B. Alston, T. Umbleja, C. M. Shikuma, and for the AIDS Clinical Trials Group Protocol A5079 Effects of Testosterone Supplementation on Whole Body and Regional Fat Mass and Distribution in Human Immunodeficiency Virus-Infected Men with Abdominal Obesity J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1049 - 1057. [Abstract] [Full Text] [PDF]



THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM HOME

S. Bhasin, G. R. Cunningham, F. J. Hayes, A. M. Matsumoto, P. J. Snyder, R. S. Swerdloff, and V. M. Montori Testosterone Therapy in Adult Men with Androgen Deficiency

Syndromes: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 1995 - 2010. [Abstract] [Full Text] [PDF]



THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM HOME

A. B. Singh, K. Norris, N. Modi, I. Sinha-Hikim, R. Shen, T. Davidson, and S. Bhasin

Pharmacokinetics of a Transdermal Testosterone System in Men with End Stage Renal Disease Receiving Maintenance Hemodialysis and Healthy Hypogonadal Men

J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2437 - 2445. [Abstract] [Full Text] [PDF]



THE JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

M. Javanbakht, A. B. Singh, N. A. Mazer, G. Beall, I. Sinha-Hikim, R. Shen, and S. Bhasin

Pharmacokinetics of a Novel Testosterone Matrix Transdermal System in Healthy, Premenopausal Women and Women Infected with the Human Immunodeficiency Virus J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2395 - 2401. [Abstract] [Full Text]



JAMA HOME S. Bhasin, T. W. Storer, M. Javanbakht, N. Berman, K. E. Yarasheski, J. Phillips, M. Dike, I. Sinha-Hikim, R. Shen, R. D. Hays, *et al.* Testosterone Replacement and Resistance Exercise in HIV-Infected Men With Weight Loss and Low Testosterone Levels JAMA, February 9, 2000; 283(6): 763 - 770. [Abstract] [Full Text] [PDF]